Skip to content
PeptideTech
Cart

Home / Research library / Tesofensine Capsules

Other compounds

Tesofensine Capsules: molecular data, studies & sources

Tesofensine Capsules is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C17H23Cl2NO
Molecular weight (MW)
328.3 g/mol
PubChem compound ID
11370864
Record title
Tesofensine

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 11370864 · retrieved 2026-09-21

2D molecular structure for Tesofensine Capsules, PubChem CID 11370864
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane
InChIKey
VCVWXKKWDOJNIT-ZOMKSWQUSA-N
SMILES
CCOC[C@H]1[C@H]2CC[C@H](N2C)C[C@@H]1C3=CC(=C(C=C3)Cl)Cl
Machine-readable PubChem source
Calculated molecular descriptors
Monoisotopic (exact) mass327.1157 Da
Heavy atoms21
Hydrogen-bond donors0
Hydrogen-bond acceptors2
Rotatable bonds4
Topological polar surface area12.5 Ų
Calculated logP (Crippen)4.60
Rings3
Stereocenters4
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Tesofensine as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

9 registered studies matched.

StudyPhase · statusConditionsSponsor · size
A 24-week Phase 2, Double-blind, Randomized, Placebo- Controlled, Single-center Safety and Efficacy Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO), and With a 24-week Open-label Extension, in Total 48 WeeksNCT03845075 · start 2019-02-25 · primary completion 2020-10-16Phase 2CompletedHypothalamic Injury-induced Obesity (HIO)Saniona21 participants
A Randomized, Open-label, Single-dose, Parallel-arm, Phase 1 Study to Investigate the Pharmacokinetic Profile of a Fixed-Dose Combination Tablet of Tesofensine and Metoprolol (Tesomet) and Co-Administration of Tesofensine Plus Commercial Metoprolol in Adult Healthy SubjectsNCT03286829 · start 2017-12-18 · primary completion 2018-02-06Phase 1CompletedHealthy Male SubjectsSaniona60 participants
A Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Multi-Center Safety and Efficacy Study of Co-Administration of Tesofensine/Metoprolol for 12 Weeks in Adult and Adolescent Patients With Prader-Willi Syndrome (PWS), Followed by Two Open Label 12 Weeks Extension Periods for Adolescent PatientsNCT03149445 · start 2017-03-30 · primary completion 2019-07-22Phase 2CompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeSaniona18 participants
A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)NCT02737891 · start 2016-04 · primary completion 2017-01Phase 2CompletedType 2 Diabetes MellitusSaniona60 participants
Evaluation of Long Term Safety of Tesofensine in Patients With ObesityNCT00481104 · start 2007-05 · primary completion 2008-09Phase 2CompletedObesityNeuroSearch A/S140 participants
The Effect of Tesofensine on Energy Balance in Humans. A Randomised, Double-Blind, Placebo-Controlled, Parallel- Group, Single Centre Study.NCT00428415 · start 2007-03 · primary completion 2007-12Phase 1 / Phase 2CompletedObesityNeuroSearch A/S32 participants
Effect of Tesofensine on Weight Reduction in Patients With Obesity. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study.NCT00394667 · start 2006-09Phase 2CompletedObesityNeuroSearch A/S200 participants
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Exploratory Study of NS 2330 (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations (Study for Proof of Concept in ADVAnced Parkinson Disease of NS 2330 / ADVANS)NCT00148512 · start 2003-03 · primary completion 2005-02Phase 2CompletedParkinson DiseaseBoehringer Ingelheim254 participants
A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeNCT00153010 · start 2003-02 · primary completion 2005-03Phase 2CompletedAlzheimer DiseaseBoehringer Ingelheim430 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

    Schoedel KA, Meier D, Chakraborty B et al. · Clinical pharmacology and therapeutics · 2010

    PMID 20520602 · DOI: 10.1038/clpt.2010.67

  2. Human study · PubMed trial index

    Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

    Astrup A, Madsbad S, Breum L et al. · Lancet (London, England) · 2008

    PMID 18950853 · DOI: 10.1016/S0140-6736(08)61525-1

  3. Human study · PubMed trial index

    [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

    Nielsen AL, Larsen TM, Madsbad S et al. · Ugeskrift for laeger · 2009

    PMID 19824222

  4. Human study · PubMed trial index

    Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study.

    Rascol O, Poewe W, Lees A et al. · Archives of neurology · 2008

    PMID 18474731 · DOI: 10.1001/archneur.65.5.577

  5. Human study · PubMed trial index

    A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

    Lehr T, Staab A, Tillmann C et al. · Clinical pharmacokinetics · 2009

    PMID 19705923 · DOI: 10.2165/11313370-000000000-00000

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Review · secondary evidence

    Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.

    Bello NT, Zahner MR · Current opinion in investigational drugs (London, England : 2000) · 2009

    PMID 19777399

  2. Preclinical / laboratory research

    Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.

    Perez CI, Luis-Islas J, Lopez A et al. · PloS one · 2024

    PMID 38656972 · DOI: 10.1371/journal.pone.0300544

Tesofensine Capsules supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Tesofensine Capsules for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
Amino USAUSD500mcg×30 Capsules1 recorded offers500mcg×30 Capsules · $124.99Checked Oct 7, 2026Supplier listing
Cenexa LabsUSD500mcg×60 Capsules1 recorded offers500mcg×60 Capsules · $136.99Checked Oct 7, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles